top of page
Taran Therapeutics
Writer
Corporate Communications
More actions
Profile
Join date: Sep 2, 2025
Posts (4)
Nov 10, 2025 ∙ 7 min
Taran Therapeutics Reports Publication of ASH Abstracts for Clinical Treatment with Lenzilumab in Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
- CR or mCR in 86% of patients within the first 12 months - Venetoclax-resistant secondary AML transformed from CMML responds to lenzilumab Burlingame, CA – (November 4, 2025) – Taran Therapeutics (“Taran”) a privately held company focused on hematology/oncology, announced American Society of Hematology (“ASH”) accepted abstracts for lenzilumab (“LENZ”) at the 67 th . ASH medical conference to be held December 4-7, 2025, in Orlando, FL. Abstract number abs25-9821, titled ‘Durable...
109
0
Aug 1, 2025 ∙ 8 min
Taran Therapeutics Presents Promising Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia and Secondary Acute Myeloid Leukemia Treatment
Taran Therapeutics Presents Promising Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia and Secondary Acute Myeloid Leukemia Treatment
97
0
Jul 28, 2025 ∙ 8 min
Taran Therapeutics Reports Publication from PREACH-M Trial for Chronic Myelomonocytic Leukemia in Current Edition of the European Medical Journal
Taran Therapeutics Reports Publication from PREACH-M Trial for Chronic Myelomonocytic Leukemia in Current Edition of the European Medical Journal
38
0
bottom of page